EN | RU
EN | RU

Help Support

Back

Efficacy of Bilastine for treatment of chronic urticaria patients

Chronic Urticaria Chronic Urticaria
Chronic Urticaria Chronic Urticaria

A study was carried out for assessing Bilastine's safety and efficacy in the treatment of chronic urticaria symptoms and to offer an evidence-based reference for clinical rational drug usage.

See All

Key take away

In people with chronic urticaria, Bilastine use is associated with significant improvements in clinical symptoms and quality of life.

Background

A study was carried out for assessing Bilastine's safety and efficacy in the treatment of chronic urticaria symptoms and to offer an evidence-based reference for clinical rational drug usage.

Method

For collecting studies on the impact of Bilastine on people with chronic urticaria, PubMed, Scopus, the Cochrane Library, Embase, EBSCO, and other databases were comprehensively explored.  Two researchers independently reviewed the literature, collected data, and assessed the inclusion study's risk of bias. The meta-analysis was carried out with software RevMan5.4.

Result

Overall, 7 trials and 975 patients were included. The skin quality of life index (Dermatology Life Quality Index, DLQI score, MD = −4.98), skin symptom score (Total Symptom Score, TSS, MD = −1.62), and  number of hives in a week (Urticaria activity score, UAS-7, MD = −25.28) were all considerably improved by Bilastine when compared to the control group. The differences were witnessed to be statistically significant.

Conclusion

Bilastine effectively improves clinical symptoms and quality of life in patients suffering from chronic urticaria.

Source:

International Archives of Allergy and Immunology

Article:

Effect of Bilastine on Chronic Urticaria: A Systematic Review and Meta-Analysis

Authors:

Xue X et al.

Comments (0)

You want to delete this comment? Please mention comment Invalid Text Content Text Content cannot me more than 1000 Something Went Wrong Cancel Confirm Confirm Delete Hide Replies View Replies View Replies en
Try: